However, a dose–responsefor tumor cytolytic phenotypes was observed for CDK4/6 inhibitors only undertumor spheroid treatment; only the highest dose of this compound on T-cells wasable to enhance T-cell-mediated anti-tumor function (SupplementaryFig. 5). Here, CDK4 is linked to neoplasm.